Orphan Drugs Market to grow at a CAGR of 6.92% during 2026 to 2035; Driven by Rising Prevalence of Rare Diseases and Increasing Development of Orphan Drug Therapies

Market Research Future (MRFR) has published an updated report on the global Orphan Drugs Market, valuing the market at USD 247.22 billion in 2025 and projecting it to grow from USD 263.10 billion in 2026, reaching USD 456.18 billion by 2035 at a compound annual growth rate (CAGR) of 6.92% during the forecast period 2026--2035.

The market is being altered by the ongoing growth of orphan product designation pipelines, the acceleration of innovation in gene therapy and biologics, and AI-driven adaptive clinical trials that are reducing development timeframes by up to 45%.

Market Overview

Orphan pharmaceuticals have become a strategic requirement for pharmaceutical corporations globally as the industry moves from volume-based to value-based therapeutic research. The combination of faster regulatory routes, one-off curative gene therapies and digital patient registries is radically changing how rare illness medications reach patients, generating a strong growth environment for biopharma sponsors around the world.

North America holds the largest market share of over 48.8% in the global market owing to the lucrative reimbursement for the small patient population therapy and the strong designation structure of the FDA. Europe has ~ 27% of the global market and is anchored by the developing incentive system of the EMA. The Asia-Pacific region is expected to be the fastest-growing region with an estimated CAGR of 12.18% through 2035, driven by China’s expanded rare-disease catalog and Japan’s SAKIGAKE accelerated pathway.

Key Market Trends & Growth Drivers

• Fast-tracked Regulatory Designations: The FDA’s Office of Orphan Products Development approved over 620 new orphan designations in 2024, up 15% year-on-year, as sponsors become more confident in the Orphan Drugs Market. The Orphan Drug Act’s bundle of tax credits, fee waivers and seven years of commercial exclusivity continues to draw investment in medicines for rare diseases. Over the same period, the parallel framework in Europe under Regulation (EC) No 141/2000 yielded 248 positive opinions, directly expanding the addressable market.


• Gene Therapy and Biologics Pipeline Expansion: The number of approved gene therapies for rare diseases will grow from 7 in 2020 to 23 by year-end 2024, with 40+ candidates in pivotal studies. In 2024, the average launch price for gene therapies for ultra-rare disease drugs was more than USD 1.5 million per patient, reflecting both the curative potential and the small patient populations. Novartis and bluebird bio, among others, have demonstrated that one-time cures can be sold at a premium price when clinical outcomes are durable.


• AI-Enabled Adaptive Clinical Trials: The revolution in the delivery of drugs for rare genetic disorders to the clinic by artificial intelligence. Some rare indications have seen 40-50% reductions in Phase II timelines and estimated USD 15-25 million reductions in costs per trial using Bayesian adaptive designs with machine learning. Companies such as Recursion Pharmaceuticals and Insilico Medicine are using AI-first approaches to target identification, hoping to bring the normal five-year discovery process down to less than 18 months.


• Digital Patient Registries: More than 6,200 rare conditions are now included in national and cross-border patient registries (e.g., the NIH's Genetic and Rare Diseases Information Center and Japan's IRUD initiative). These registries speed up patient enrollment for rare disease therapy trials, cutting recruiting times from years to months. Regulators are increasingly accepting real-world evidence generated from registry data as supplementary evidence for marketing authorization.


• Newborn Screening Expansion: The US Recommended Uniform Screening Panel has expanded to 63 conditions by 2024, and the EU screening directive is encouraging member states to adopt harmonized panels. Early diagnosis directly expands the potential patient pool for rare disease treatments. It shifts the initiation of treatment to the presymptomatic phase, thereby improving outcomes and allowing for premium pricing of ultra-rare condition medications.

Market Segmentation Insights

By Drug Type: Biologics lead the way, holding roughly 70.2% of the Orphan Drugs Market in 2025, driven by the growing pipelines in gene therapy and monoclonal antibodies. Monoclonal antibodies, gene therapies and recombinant proteins together make up the fastest-growing class of modalities for rare disease treatments. Non-biologics are expected to grow at a CAGR of 5.14% through 2035, driven by next-generation small-molecule platforms for rare genetic disorder drugs.

By Disease Area: Oncologic diseases are projected to dominate with $93.27 billion in 2025, indicating the predominance of designated orphan drug status approvals in hematologic malignancies. Neurologic disorders are the fastest-growing segment of disease with a 13.85% CAGR through 2035, driven by breakthrough rare disease therapies like nusinersen and newer intrathecal gene therapies for spinal muscular atrophy and other neurodegenerative disorders.

By Route of Administration: The Parenteral Delivery Orphan Drugs Market is expected to hold a 75.1% share in 2025, driven by the need for infusion of biologics. Infusion centers in hospitals are the primary site of care for small patient populations. Formulation science is improving bioavailability for ultra-rare condition drugs and enabling at home dosage, and oral therapies are predicted to witness a CAGR of 12.82% through 2035.

By Distribution Channel: Hospital pharmacies are anticipated to hold around 66.9% of distribution in 2025, driven by the clinical complexity and cold-chain distribution requirements of rare illness drugs. The fastest-growing channel is online pharmacies, with a CAGR of 14.25%. This is driven by direct-to-patient models and specialist pharmacies digitizing for chronic-dosing uncommon genetic condition medications.

Regional Landscape

North America -- Technology Adoption Leader

Orphan Drugs Market is dominated by North America, which holds over 48.8% share of the worldwide market. The region’s growth is underpinned by a strong framework of designations from the FDA, a reimbursement landscape that enables premium pricing for therapies with designated orphan drug status, and the greatest global pipeline of drugs for rare genetic disorders. The United States (US) dominates the region with 88.2% of regional revenue, driven by Orphan Drug Act incentives and broad commercial payer adoption. Canada also has a key role, with the national Rare Disease Drug Strategy introduced in Budget 2023 providing CAD 1.5 billion of dedicated funding for small patient population therapy access. Mexico is becoming a growth market, and regulatory modernization at COFEPRIS is gradually aligning with US and EU norms for rare illness medicines.

Europe -- Emerging Market Dynamics

Europe makes up roughly 27% of the worldwide market, fuelled by the EMA’s expanding incentive system, cross-border health technology assessment cooperation and centralised procurement. Germany has the highest regional adoption rate at 24.5% of regional revenue. However, its AMNOG procedure now requires further benefit re-evaluation at year five for items receiving designated orphan medicine classification with annual sales of more than EUR 50 million. The United Kingdom is next with an 8.42% CAGR, underpinned by the NICE Highly Specialised Technologies pathway. France, Italy and Spain complete the major markets. Nordic countries are leading cross-border procurement collaborations. An expanding pool of gene therapy specialists and key players like Novartis AG and F. Hoffmann-La Roche AG are ramping up rivalry, fueling innovation.

Asia-Pacific -- Rapid Growth and Innovation

Asia-Pacific is expected to be the fastest-growing region in the Orphan Drugs Market with a CAGR of 12.18% during the forecast period 2023-2035. Growth is being driven by larger rare-disease catalogues, faster regulatory pathways and increased diagnostic access, especially in China and Japan. China is leading the area with a CAGR of 14.25%, adding 86 ailments to its National Rare Disease List in 2023 and adopting zero-tariff import regulations for products with designated orphan medicine status. The IRUD program and SAKIGAKE designation in Japan have directly contributed to the pipeline for rare genetic condition drug development, via screening of more than 50,000 undiagnosed individuals. The Revised National Policy for Rare Diseases in India provides funding up to INR 50 Lakh per patient for therapies that are classified as orphan drugs.

Middle East and Africa -- Untapped Market Potential\

The Middle East and Africa area has a lower but fast-growing part of the global market, spurred by ambitious national health transformation agendas and more investment in rare disease infrastructure. Saudi Arabia has the largest share of 35.2% in the region. Under Vision 2030, more than USD 65 billion has been allocated as cumulative health infrastructure spending, with rare disease treatments as a priority therapeutic area. The UAE is using its status as a medical tourism centre to build Dubai Healthcare City as a regional distribution centre for the treating of small patient populations. The South African regulator SAHPRA is implementing an accelerated review pathway for goods identified as orphan drugs, based on the FDA approach.

Competitive Landscape

The Orphan Drugs Market is moderately concentrated, with the top five firms contributing 35-42% of the global revenue. Some of the key players are: Novartis AG, F. Hoffmann-La Roche AG, Johnson & Johnson, Pfizer Inc., Sanofi SA, AbbVie Inc., Vertex Pharmaceuticals, BioMarin Pharmaceutical, Alexion (AstraZeneca), bluebird bio. Recent major developments include:

• December 2023 saw a global landmark in rare disease treatment with the first CRISPR-based gene editing therapy approved by the FDA and EMA – Casgevy, from Vertex Pharmaceuticals and CRISPR Therapeutics, for sickle cell disease and beta-thalassemia.


• Novartis AG finalized the acquisition of MorphoSys for around USD 2.7 billion in March 2024, bolstering its rare hematologic oncology pipeline in the Orphan Drugs Market.


• Pfizer Inc. revealed favorable Phase III data for its gene-silencing therapy for ATTR-cardiomyopathy in September 2024 and is on track to submit an NDA in 2025 as a prospective ultra-rare disease drug.


• In November 2024, China NMPA added 36 orphan-designated medications to the National Reimbursement Drug List, the largest single expansion ever in coverage of rare disease treatments in the country.


• The additional indication of Voxzogo for hypochondroplasia was approved by the FDA in March 2025, increasing the addressable population for this rare genetic condition medication therapy.


• AstraZeneca/Alexion announced a USD 1B investment in next-generation complement inhibitors for ultra-rare condition medicines in nephrology and neurology in May 2025.

Future Outlook

By 2035, further advances in gene editing platforms for ultra-rare indications, broader outcomes-based and annuity payment models, and further penetration into emerging markets in Asia-Pacific, the Middle East, and Africa are anticipated to revolutionize the Orphan Drugs Market. Companies that adopt platform technology and multi-indication strategies, regulatory harmonization and cross-border access, and patient-centric value frameworks, together with ESG integration, are well positioned to capture disproportionate growth.

Key growth opportunities highlighted in the MRFR report include the use of gene editing platforms to cure diseases that were previously thought to be incurable, development of outcomes-based reimbursement models that distribute payer risk and enable sponsor returns, and the proliferation of orphan drugs in high-growth emerging markets where the national rare-disease policies and zero-tariff import policies of countries are establishing a baseline demand for drugs that cure rare genetic disorders.